RIVER STONE BIOTECH APS has a total of 12 patent applications. It increased the IP activity by 600.0%. Its first patent ever was published in 2017. It filed its patents most often in WIPO (World Intellectual Property Organization), Australia and Canada. Its main competitors in its focus markets biotechnology, foods and drinks and organic fine chemistry are SCIENTIST OF FORTUNE SA, ENOBRAQ and C LECTA GMBH.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 6 | |
#2 | Australia | 2 | |
#3 | Canada | 2 | |
#4 | EPO (European Patent Office) | 1 | |
#5 | Mexico | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Foods and drinks | |
#3 | Organic fine chemistry | |
#4 | Pharmaceuticals |
# | Technology | |
---|---|---|
#1 | Microorganisms | |
#2 | Fermentation | |
#3 | Enzymes | |
#4 | Heterocyclic compounds | |
#5 | Medical preparations | |
#6 | Peptides |
# | Name | Total Patents |
---|---|---|
#1 | Schwab Markus | 5 |
#2 | Hansen Esben | 4 |
#3 | Houghton-Larsen Jens | 3 |
#4 | Kannangara Rubini Maya | 3 |
#5 | Sheridan Joseph Michael | 3 |
#6 | Malca Sumire Honda | 3 |
#7 | Heal Jon Richard | 3 |
#8 | Berninger Philipp Friedrich | 3 |
#9 | Santella Marco | 3 |
#10 | Hallwyl Swee | 3 |
Publication | Filing date | Title |
---|---|---|
WO2021069714A1 | Genetically modified host cells producing benzylisoquinoline alkaloids | |
WO2021048172A2 | Delivery vehicle for in situ delivering of pharmaceutical agents | |
WO2020144371A1 | Recombinant host cells with improved production of l-dopa, dopamine, (s)-norcoclaurine or derivatives thereof. | |
WO2020078837A1 | Microbial cell with improved in vivo conversion of thebaine/oripavine | |
AU2018285734A1 | Demethylation of reticuline and derivatives thereof with fungal cytochrome P450 | |
WO2018229305A1 | Norcoclaurine synthases with increased activity |